Overview

Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

Status:
Not yet recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

Summary

Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

Phase:

Phase 2

Details

Lead Sponsor:

Wuhan Union Hospital, China

Treatments:

Antibodies, Monoclonal
Durvalumab